<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633733</url>
  </required_header>
  <id_info>
    <org_study_id>HL237-103</org_study_id>
    <nct_id>NCT04633733</nct_id>
  </id_info>
  <brief_title>The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus</brief_title>
  <official_title>An Open-label, Multiple-dose, Fixed-sequence, 3-Period Study to Evaluate the Pharmacokinetic Interactions Between HL237 and Tacrolimus in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the pharmacokinetic interaction between HL237 and tacrolimus in&#xD;
      healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the pharmacokinetic interaction by comparing of pharmacokinetic parameters when&#xD;
      administered HL237(or tacrolimus) between with tacrolimus(or HL237) and without tacrolimus(or&#xD;
      HL237).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 22, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Actual">September 24, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Fixed-sequential</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration at steady state(Cmax,ss) of HL237</measure>
    <time_frame>0(before dosing), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 hour(after dosing) on day 21 and day 22</time_frame>
    <description>Comparison of pharmacokinetic parameters between when administered tacrolimus with HL237 and without HL237</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve during a dosage interval(AUCτ) of HL237</measure>
    <time_frame>0(before dosing), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 hour(after dosing) on day 21 and day 22</time_frame>
    <description>Comparison of pharmacokinetic parameters between when administered tacrolimus with HL237 and without HL237</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak whole-blood concentration(Cmax) of tacrolimus</measure>
    <time_frame>0(before dosing), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72hour(after dosing) on day 1 and day 22</time_frame>
    <description>Comparison of pharmacokinetic parameters between when administered tacrolimus with HL237 and without HL237</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the whole-blood concentration versus time curve from time zero to time of last measurable concentration(AUClast) of tacrolimus</measure>
    <time_frame>0(before dosing), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72hour(after dosing) on day 1 and day 22</time_frame>
    <description>Comparison of pharmacokinetic parameters between when administered tacrolimus with HL237 and without HL237</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This single arm is conducted in fixed-sequence(Treatment A -&gt;(washout period) -&gt; Treatment B -&gt; Treatment C -&gt; Maintenance treatment).&#xD;
Treatment A : tacrolimus 5mg po single dose, Treatment B : HL237 400mg bid for 4 days, Treatment C: tacrolimus 5mg po single dose and HL237 400 mg bid, Maintenance treatment : HL237 400mg bid for 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL237 tablet</intervention_name>
    <description>HL237 400mg will be administered orally twice a day.</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus capsule</intervention_name>
    <description>tacrolimus 5mg will be administered orally once a day.</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male, 19 years ≤ age ≤ 45&#xD;
&#xD;
          -  Body weight ≥ 50kg and 18.5 ≤ BMI ≤ 29.9kg/m2&#xD;
&#xD;
          -  Subjects are agree to use contraceptives that protocol suggest and not provide sperm&#xD;
             for up to 2 months after the last administration of the investigational drug&#xD;
&#xD;
          -  Volunteer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with serious cardiovascular, respiratory, hepatology, renal, hematologic,&#xD;
             gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history&#xD;
             of such disease&#xD;
&#xD;
          -  Subject with symptoms of acute disease within 28 days prior to investigational&#xD;
             products dosing&#xD;
&#xD;
          -  Subject with medical history which able to affect absorption, distribution, metabolism&#xD;
             and excretion of drug&#xD;
&#xD;
          -  Subject with hypersensitive reaction to following drug or history of clinically&#xD;
             significant hypersensitive reaction to following drug&#xD;
&#xD;
               -  Calcineurin inhibitor or Macrolides&#xD;
&#xD;
               -  HL237&#xD;
&#xD;
          -  Subject with clinically significant active chronic disease&#xD;
&#xD;
          -  Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency&#xD;
             or glucosegalactose malabsorption&#xD;
&#xD;
          -  Subjects who showed one or more of the following in a screening test including a&#xD;
             retest&#xD;
&#xD;
               -  AST, ALT &gt; UNL (upper normal limit) x 2.5&#xD;
&#xD;
               -  Creatinine clearance =&lt; 80mL/min (Cockcroft-Gault GFR = (140-age) * (Wt in kg) /&#xD;
                  (72 * Cr))&#xD;
&#xD;
               -  Results of ECG, QTc &gt; 450 msec&#xD;
&#xD;
          -  Positive test results for hepatitis B virus surface antigen, anti-hepatitis C virus&#xD;
             antibody, anti-Human Immunodeficiency virus antibody or venereal disease research&#xD;
             laboratory test&#xD;
&#xD;
          -  Use of any prescription medication within 14 days prior to study medication dosing&#xD;
&#xD;
          -  Use of any over-the-counter(OTC) medication within 7 days prior to study medication&#xD;
             dosing&#xD;
&#xD;
          -  Subject with clinically significant allergic disease (except for mild allergic&#xD;
             rhinitis and mild allergic dermatitis that are not needed to administer drug)&#xD;
&#xD;
          -  Subject who is not able to taking standard meals provided by the institution&#xD;
&#xD;
          -  Subject with whole blood donation within 60 days, component blood donation within 20&#xD;
             days&#xD;
&#xD;
          -  Subjects receiving blood transfusion within 30 days prior to study medication dosing&#xD;
&#xD;
          -  Participation in any clinical investigation within 6 months prior to study medication&#xD;
             dosing&#xD;
&#xD;
          -  Use of any medication effected on drug enzyme induction or inhibition such as&#xD;
             barbitals within 30 days prior to study medication dosing&#xD;
&#xD;
          -  Subjects who have continuously consumed grapefruit juice or caffeine (grapefruit juice&#xD;
             or caffeine &gt; 5 cups/day), or who can't refrain from intake during hospitalization&#xD;
&#xD;
          -  Subjects who have continued to drink alcohol (alcohol&gt; 30 g/day) or who can't quit&#xD;
             drinking during hospitalization&#xD;
&#xD;
          -  Severe heavy smoker(cigarette &gt; 10 cigarettes per day) or subjects who can't quit&#xD;
             smoking during hospitalization&#xD;
&#xD;
          -  Subjects that the investigator deems unsuitable for participation in the clinical&#xD;
             trial due to laboratory test results or other excuse such as non-responding to request&#xD;
             or instruction by investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Korea Univertisy Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

